drugset / Trial / NCT05828836

Allopurinol and Quality of Life in Liver Cirrhosis

NCT05828836

Phase 2/3 Completed 100 enrolled Tanta University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study aims to evaluate the impact of allopurinol on patients' related quality of life.

Timeline

Start
2022-06-15
Primary completion
2023-01-15
Completion
2023-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule 300 mg

Indications